TIZONA THERAPEUTICS
Live / Registered — Registered (as of 27 Oct 2020)
What this means for you
Registered since 27 Oct 2020. The owner can stop confusingly similar uses in the classes it covers; it stays on the register as long as the owner keeps up the maintenance filings (the §8 declaration of use was due 27 Oct 2026; it can still be filed, with a surcharge, until 27 Apr 2027).
Record
- Serial number
- 86984567
- Registration number
- 6185401
- Mark type
- Word mark
- Filed
- 10 Jun 2015
- Published for opposition
- 08 Dec 2015
- Registered
- 27 Oct 2020
- Next maintenance filing
- §8 declaration of use, due by 27 Oct 2026 (grace period to 27 Apr 2027)
- Attorney of record
- Sharon Smith
Goods and services
- Class 042 — Scientific and technological services: Research and development of pharmaceuticals and compounds for the treatment of cancer and autoimmune diseases; research and development of pharmaceuticals and compounds for modulation of the immune system and the tumor microenvironment
Owner
- TIZONA THERAPEUTICS, INC., South San Francisco, CA, US
- TIZONA THERAPEUTICS, INC., South San Francisco, CA, US
- Vesuvius Pharmaceuticals, Inc., Cambridge, MA, US
- Vesuvius Pharmaceuticals, Inc., Cambridge, MA, US
Prosecution history
- 27 Oct 2025 — COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
- 27 Oct 2020 — REGISTERED-PRINCIPAL REGISTER
- 25 Sept 2020 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 24 Sept 2020 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 24 Sept 2020 — EXAMINER'S AMENDMENT ENTERED
- 24 Sept 2020 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
- 24 Sept 2020 — EXAMINERS AMENDMENT E-MAILED
- 24 Sept 2020 — SU-EXAMINER'S AMENDMENT WRITTEN
- 09 Sept 2020 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 09 Sept 2020 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 09 Sept 2020 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 27 Jul 2020 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 27 Jul 2020 — NON-FINAL ACTION E-MAILED
- 27 Jul 2020 — SU - NON-FINAL ACTION - WRITTEN
- 24 Jun 2020 — STATEMENT OF USE PROCESSING COMPLETE